Venous thromboembolism treatment duration in autoimmune diseases. Research trends

Published:October 26, 2021DOI:https://doi.org/10.1016/j.ejim.2021.10.020

      Highlights

      • Venous thromboembolism (VTE) is a common event among autoimmune diseases.
      • Recurrent VTE is known to be increased on these patients after treatment discontinuation.
      • VTE treatment duration in autoimmune diseases is currently on investigation.
      • Randomized trials are lacking and observational registries provide the best available evidence so far.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Yamashita Y
        • Morimoto T
        • Kadota K
        • Ono K
        • Kimura T.
        Autoimmune disorders and venous thromboembolism: an update from the COMMAND VTE registry.
        Eur J Intern Med. 2021; 84: 106-108
        • Sada PR
        • López-Núñez JJ
        • Samperiz A
        • Soto MJ
        • Pedrajas JM
        • Porras JA
        • et al.
        Venous thromboembolism in patients with autoimmune disorders: findings from the RIETE registry [published correction appears in Angiology. 2020 May;71(5):482].
        Angiology. 2020; 71: 131-138
        • Borjas Howard J
        • Ruiz-Sada P
        • de Leeuw K
        • López-Jimñenez L
        • Font C
        • Marchena PJ
        • et al.
        Risk of recurrent venous thromboembolism in patients with autoimmune diseases: data from the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) registry.
        Br J Haematol. 2021; 194: 195-199
        • Gussoni G
        • Frasson S
        • La Regina M
        • Di Micco P
        • Monreal M
        • RIETE Investigators
        Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry.
        Thromb Res. 2013; 131: 24-30
        • Konstantinides SV
        • Meyer G.
        The 2019 ESC guidelines on the diagnosis and man- agement of acute pulmonary embolism.
        Eur Heart J. 2019; 40: 3453-3455
        • Romero-Díaz J
        • García-Sosa I
        • Sánchez-Guerrero J.
        Thrombosis in systemic lupus erythematosus and other autoimmune diseases of recent onset.
        J Rheumatol. 2009; 36: 68-75
        • Molander V
        • Bower H
        • Frisell T
        • Askling J.
        Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden.
        Ann Rheum Dis. 2021; 80: 169-175
        • Desbois AC
        • Wechsler B
        • Resche-Rigon M
        • Piette JC
        • Huong DLT
        • Amoura Z
        • et al.
        Immunosuppressants reduce venous thrombosis relapse in Behçet's disease.
        Arthritis Rheum. 2012; 64: 2753-2760
        • - Grainge MJ
        • West J
        • Card TR.
        Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study.
        Lancet. 2010; 375: 657-663